Welcome to our dedicated page for Propanc Bio news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on Propanc Bio stock.
Propanc Biopharma, Inc. (PPCB) is a clinical-stage biopharmaceutical company pioneering enzyme-based therapies targeting aggressive cancers. This dedicated news hub provides investors and researchers with essential updates on preclinical developments, strategic partnerships, and regulatory milestones.
Access timely press releases covering PPCB's lead candidate PRP, designed for pancreatic and ovarian cancers, along with progress reports from collaborative research initiatives. Our curated feed includes financial filings, intellectual property updates, and scientific presentations - all critical for tracking this innovative oncology developer.
Bookmark this page to monitor PPCB's progress in advancing synergistic enzyme formulations through preclinical studies. Stay informed about emerging research from their POP1 joint program and other academic collaborations shaping next-generation cancer therapies.
Propanc Biopharma (OTC Pink: PPCB) announces that its lead asset, PRP, could potentially solve the problem affecting response rates of immune checkpoint inhibitors in treating PD-L1-High solid tumors. Dr. Julian Kenyon, CSO, predicts that pretreatment with PRP could reverse the promotion of epithelial to mesenchymal transition (EMT) pathways induced by PD-L1, which are responsible for tumor growth and metastasis.
The Immune Checkpoint Inhibitors Market, valued at $47.22 Billion in 2023, is expected to reach $158.26 Billion by 2031. However, response rates for most solid tumors range only between 15-30%. A recent study in the British Journal of Cancer suggests that EMT induced by tumor cell-intrinsic PD-L1 signaling predicts poor response to immune checkpoint inhibitors in PD-L1-High lung cancer.
Dr. Kenyon believes PRP could enable PD-L1 non-responders to become responders by inducing cell differentiation in cancer cells, reversing EMT pathways, and reducing metastatic potential.
Propanc Biopharma, a biopharmaceutical company, announced receiving a Certificate of Grant for its “proenzymes composition” patent from the Japanese Patent Office, marking its fourth Japanese patent. This patent covers dosing regimen claims for PRP, the company's lead asset, advancing to clinical development. Additionally, the Intellectual Property of Malaysia granted a patent for a cancer treatment using trypsinogen and chymotrypsinogen, the company's third patent in Malaysia. Propanc's intellectual property portfolio now includes 93 patents worldwide for using PRP against solid tumors. Japan's pharmaceutical market, projected to reach $46.36 billion in 2024, is a key market for Propanc. The company aims to advance PRP into a Phase 1b clinical study, targeting and eradicating cancer stem cells without severe side effects.
FAQ
What is the current stock price of Propanc Bio (PPCB)?
What is the market cap of Propanc Bio (PPCB)?
